Industries > Pharma > Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

PUBLISHED: 19 May 2017
PAGES: 204
PRODUCT CODE: PHA0194

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 72 figures – all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
– Infliximab
– Rituximab
– Abciximab
– Trastuzumab
– Adalimumab
– Bevacizumab

• This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
– Remsima/Inflectra
– Infimab
– Reditux
– BI695500
– CT-P10
– BI695501
– FKB327
– FKB238
– Mabtas
– AcellBia
– Maball
– Clotinab
– Abcixirel
– BCD-022
– BCD-021
– Herzuma
– CANMAB/Hertraz

• Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
– The US Biosimilar mAb Market
– Japanese Biosimilar mAb Market
– EU5 Biosimilar mAb Markets
– BRIC and South Korea Biosimilar mAb Markets
– Rest of the World Biosimilar mAb Market

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

    Download sample pages

    Complete the form below to download your free sample pages for Global Biosimilar Monoclonal Antibodies Forecast 2017-2027

      Latest Pharma news

      Visiongain Publishes Pharma Wholesale and Distribution Market Report 2024-2034

      The global Pharma Wholesale and Distribution market is estimated at US$844.2 billion in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period 2024-2034.

      20 February 2024

      READ

      Visiongain Publishes Biobanking Market Report 2024-2034

      The global Biobanking market is estimated at US$75.4 billion in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period 2024-2034.

      19 February 2024

      READ

      Visiongain Publishes Dermatological Drugs Market Report 2024-2034

      The Dermatological Drugs market is estimated at US$30.47 billion in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period 2024-2034.

      13 February 2024

      READ

      Visiongain Publishes Allergic Rhinitis Drugs Market Report 2024-2034

      The global Allergic Rhinitis Drugs market is estimated at US$16,821.6 million in 2024 and is expected to register a CAGR of 2.7% from 2024 to 2034.

      12 February 2024

      READ